EUVIMEDEUVIMED entdecken
Crossref

Incidence of and Factors Associated with Hypokalemia During Sulbactam/Ampicillin Therapy: A Retrospective Observational Study

Kazutaka Uchida, Kenshiro Higashi, Yoshihiro Nakagawa, Kazutaka Oda

Hospital Pharmacy · 18.11.2026

DOI: 10.1177/00185787261502964 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hospital Pharmacy, online erschienen am 18.11.2026. Verfasst von Kazutaka Uchida und 3 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The antimicrobial agent sulbactam/ampicillin (SBT/ABPC) is used to treat a wide range of infections; however, hypokalemia has recently attracted attention as an adverse event of SBT/ABPC. Risk factors for this condition have not been fully characterized, and preventive strategies remain unclear.

Objective

To investigate the incidence of hypokalemia and identify factors associated with its occurrence during sulbactam/ampicillin therapy.

Methods

This single-center retrospective observational study used routinely collected electronic medical record data from hospitalized patients aged ≥ 20 years without hypokalemia at the initiation of SBT/ABPC therapy who received SBT/ABPC for >2 consecutive days at a hospital in Japan between January 1, 2022, and December 31, 2024. Patients undergoing hemodialysis, those with hypokalemia at the initiation of SBT/ABPC therapy, and those lacking the required laboratory or body weight data were excluded. The primary endpoint was the identification of factors associated with hypokalemia during SBT/ABPC therapy.

Results

Of the 269 patients who received SBT/ABPC during the study period, 182 were included in the analysis. Hypokalemia occurred in 39 patients (21.4%), of whom 6 had a nadir serum potassium concentration ≤ 3.0 mEq/L. The median time to onset was 4 days (range, 2-13 days). Survival classification and regression tree analysis identified a baseline serum potassium level of ≤3.9 mEq/L ( P < .001) and age >75 years ( P = .008) as factors associated with the occurrence of hypokalemia. Conclusion and relevance: Close monitoring for hypokalemia may be warranted in patients aged > 75 years with a baseline serum potassium level of ≤3.9 mEq/L. In such patients, serum potassium measurement within the first several days after initiation of SBT/ABPC therapy, particularly around days 4 to 5, should be considered.

Zitieren

APA

Uchida, K., Higashi, K., Nakagawa, Y., & Oda, K. (2026). Incidence of and Factors Associated with Hypokalemia During Sulbactam/Ampicillin Therapy: A Retrospective Observational Study. Hospital Pharmacy. https://doi.org/10.1177/00185787261502964

Vancouver

Uchida K, Higashi K, Nakagawa Y, Oda K. Incidence of and Factors Associated with Hypokalemia During Sulbactam/Ampicillin Therapy: A Retrospective Observational Study. Hospital Pharmacy. 2026. doi:10.1177/00185787261502964

BibTeX
@article{Uchida2026,
  author = {Uchida, Kazutaka and Higashi, Kenshiro and Nakagawa, Yoshihiro and Oda, Kazutaka},
  title = {Incidence of and Factors Associated with Hypokalemia During Sulbactam/Ampicillin Therapy: A Retrospective Observational Study},
  journal = {Hospital Pharmacy},
  year = {2026},
  doi = {10.1177/00185787261502964}
}
Kostenlos starten →